Pentobarbitone. 20 mg.kg -1 IV followed by infusion of 25 mg.kg-t.hr -1, produced a progressive decrease in mean arterial pressure in dogs from 113 +-17mmHg (SD ) after one hour of infusion to 82 +--21 mmHg after 3.5 hours and to 49 +--22 mmH g after 5.5 hours. EEG silence occurred at 3.6 • 0.6 hours. In dogs similarly treated with pentobarbitone, a two hour infusion of dopamine 5 ~g-kg-I'min -I beginning at the time of EEG silence prevented the further decrease in pressure and restored pressure to 87 • 18mmHg.
Barbiturates have been used in large doses to protect the brain from injury following hypoxia and to reduce intracranial pressure.~-4 This use may be complicated by cardiovascular depression. In a previous study 5 comparing the cardiovascular effects of thiopentone and pentobarbitone in dogs, both barbiturates produced dose-related depressions of arterial pressure and cardiac output with little change in systemic vascular resistance, At drug concentrations less than those producing EEG silence there was no significant difference between the two agents except for a higher incidence of ventricular dysrhythmias in dogs given thiopentone. At drug concentrations greater than those producing EEG silence, pentobarbitone appeared to be the safer drug.
The present study evaluates whether dopamine, administered at a dosage rate producing minimal alpha adrenergic stimulation (5 ~g-kg-i 'rain-I),6 reverses the cardiovascular depression produced by toxic doses of pentobarbitone.
Methods
Seventeen mongrel dogs of both sexes weighing 8.5 to 21.5 kg were used. An induction dose of 20 mgkg -~ pentobarbitone was followed immediately by an infusion of 25 mg.kg-i, hr-~ pentobarbitone into a foreleg vein for 5.5 hrs. The first hour of anaesthesia was used to place all recording devices. Ten blood samples (1.5 ml each) were drawn at 30 min intervals from the first hour until the end of the experiment for subsequent plasma pentobarbitone assay:
Tracheal tubes were placed and ventilation controlled with a Bennett Model BA-4 ventilator using CAN Base deficit was adjusted with sodium bicarbonate if greater than 3-4 meq'l-t. A thermistor probe was inserted in the pharynx and body temperature was maintained at 36 ~ C to 40~ by the use of a heat lamp and/or plastic covers.
A femoral artery and jugular vein were cannulated to monitor arterial pressure and central venous pressure respectively. A thermistor-tipped pulmonary arterial catheter was inserted via the femoral vein. The position of the catheter was verified by pressure wave form. Duplicate thermodilution cardiac output measurements were made using 3 ml iced normosal "m" injections. All three pressure transducers (Statham P23Db, ten volt) were connected to a Grass Model 5 polygraph. An eightchannel Grass Model 6 EEG was used to monitor cortical activity using two frontal (F3 and F4), two posterior (P3 & P4), and one central (Cz) electrodes. Leads monitored were (1) F3-C2; (2) P3-Cz;
(3) F4-Cz; (4) P4-Cz; (5) F3-P3; (6) F4-P4; and (7) F3-P3. Channel 8 was used for the electrocardiogram (ECG) signal measured across the chest wall.
Every 10-15 min EEG recordings were made. EEG silence occurred after 3.6 ---0.6 (Mean ---SD) hrs of pentobarbitone infusion at a plasma concentration of 70 ---15 mg.l -~.
Cardiovascular data measured or calculated at 30 min intervals from 1-5.5 hrs included heart rate, stroke volume/kg, cardiac output/kg, systemic vascular resistance (mean arterial pressure minus central venous pressure divided by cardiac output/kg), mean arterial pressure and central venous pressure. Dopamine (5 jxg.kg-i, min-~) was infused in five of the 17 dogs after EEG siLence was reached (at approximately 3.5 hrs) and the infusion continued for two additional hrs with cardiovascular data and plasma pentobarbitone concentrations determined at 30 rain intervals.
The remaining 12 dogs served as controls. Cardiovascular data and pentobarbitone concentrations from all 17 dogs were pooled and averaged for the first 3.5 hours (first six data points). The four data points for the control and dopamine experiments obtained after 3.5 hours were normalized to the pre-dopamine values (6th data point in Figs. 1 and 2). Statistical analyses of the dopamine effects were done using analysis of variance followed by the student-Newman-Keuls' test. 7 A P value of 0.05 or less was considered statistically significant.
Results
Following an induction dose of 20 mg.kg-t pentobarbitone and an infusion of 25 mg.kg-t.hr -I for one hour in 12 control dogs the plasma concentration averaged 42.7 mg.1-1 . Subsequent infusion at a rate of 25 mg.kg-t'hr -n for an additional 4.5 hrs resulted in a linear increase in plasma concentration. The increase averaged 11.8 -3.5 mg.kg-~.hr -t (mean -+ SD) as determined from samples taken every 30 min. The rate of change of plasma pentobarbitone concentration was 11.8 ---3.3mg'l-l'hr -I in five dogs similarly treated with pentobarbitone but in which dopamine 5 txg.kg-~.hr -~ was additionally infused at the 3.5 hr period until the 5.5 hr period.
Infusion of 25 mg-kg-t .hr-~ pentobarbitonc after an induction dose of 20 mg.kg-t resulted in concentration-dependent reductions in heart rate, stroke volume.kg -~, cardiac output.kg -t ( Fig. 1 ) and mean arterial pressure (Fig. 2 ). Dopamine infusion (5~xg'kg-l'min-l), started at approximately 3.5 hours after pentobarbitone induction, reversed the downward trend in these cardiovascular data ( Figs.  1 and 2) .
Systemic vascular resistance did not change with increasing pentobarbitone concentrations and was not significantly affected by dopamine (Fig. 2) . The course of the increase in central venous pressure seen during pentobarbitone infusion was not altered by dopamine (Fig. 2 ).
Discussion
The pharmacological actions of dopamine on the cardiovascular system are dose-dependent. At low doses two actions predominate. A release of norepinephrine from storage depots in ventricular tissue t~ ~ results in an increase in contractility n~ t and stroke volume. 12 This effect is similar to that seen with tyramine and, as with tyramine, is inhibited by reserpine and desmethylimipramine, to.in Also seen at low doses is a reduction of resistance in the renal and mesenteric circulations attributed to specific dopaminergic receptor activation. 13'14 At higher doses, actions on betat and alphan receptors become prominent resulting in an increase in heart rate, tl a further increase in contractility tl and an increase in resistance in blood vessels supplied with alpha) receptors. 15 Effects seen in this study with dopamine infused at a rate of 5 txg'kg-].min-l, namely an increase in stroke volume with little change in heart rate, are thus characteristic of those effects seen with low doses of dopamine and serve to explain the increase in mean arterial pressure. Thus pentobarbitone, in toxic doses, does not prevent the cardiac actions of dopamine involved in restoring arterial pressure. Phenobarbitone induced hypotension is also reversed by dopamine in dogs ]6'17 and in a child. ] 7 We were surprised at the continued increase in stroke volume over a period of 1 89 hrs of infusion in view of the report by Jarnberg et al. in humans ~s who stated that plasma levels of dopamine, when administered at a rate of 2 and 5 ~g'kg-l'min -1, reach a steady state in 5 min. Analysis of Figure I volume in 5 min at an infusion rate of 5 t~g-kg -t' min-i. In our study dopamine was administered at toxic plasma concentrations of pentobarbitone producing electroencephalographic silence (70 -15 mg.l-t). These concentrations are higher than those achieved by Caseby (25-40 mg.l -t) during successful treatment of a patient with postpartum stroke.2~
Since dopamine reversed the pentobarbitoneinduced decrease in mean arterial pressure and did so primarily by an effect on stroke volume it is an appropriate antagonist to the cardiovascular effects of toxic doses of pentobarbitone.
R6sum6
Le pentobarbitone administr~ d hautes doses (20 C'est par l'augmentation du d~bit cardiaque que cet effet s'est manifest~ car les r~sistances vasculaires sysMmiques n'ont pas ~t~ modifies par la dopamine. Cette augmentation de d~bit cardiaque dtait surtout le rdsultat d'une augmentation du volume d' djection car la fr(quence cardiaque s'est d peine modifi~e. Comme c'est par rdduction du volume d' gjection que le pemobarbirone avait diminud la pression artdrielle, la dopamine, en r~tablissant te volume d'~jection, apparMt donc d'un choix judicieux pour contrer les effets cardiovasculaires ind~sirables de doses toxiques de pentobarbitone.
